Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034125 | Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. | PHASE3 | COMPLETED | - | — | — | - | - | Jul 19, 2006 | 11 | United States, Argentina +3 |
| Name | Type | Description |
|---|---|---|
| LY353381 | DRUG | - |
| tamoxifen | DRUG | - |
Inclusion Criteria 1. Locally advanced or metastatic breast cancer 2. Bi-dimensionally measurable disease Exclusion Criteria 1\. Prior hormonal therapy